References

medalphabet

Медицинский алфавит

Medical alphabet

2078-56312949-2807

ООО «Альфмед»

10.33667/2078-5631-2026-3-84-92

medalphabet-4956

Research Article

Статьи

Российский междисциплинарный консенсус по определению «Сложный для ведения» и «Трудный для лечения» псориатический артрит / псориаз и ведению этих пациентов. Положения дерматовенерологов

Russian interdisciplinary consensus on the definition of “Complex to manage” and “Difficult to treat” psoriatic arthritis/psoriasis and the management of these patients. Positions of dermatovenerologists

Круглова

Л. С.

Kruglova

L. S.

Круглова Лариса Сергеевна, д.м.н., профессор, зав. кафедрой дерматовенерологии и косметологии, ректор

Москва

Kruglova Larisa S., Dr Med Sci (habil.), professor, head of Dept of Dermatovenereology and Cosmetology, rector

Moscow

kruglovals@mail.ru

Бакулев

А. Л.

Bakulev

A. L.

Бакулев Андрей Леонидович, д.м.н., профессор, профессор кафедры дерматовенерологии и косметологии, член профильной комиссии Экспертного совета Минздрава России по дерматовенерологии и косметологии, член правления Российского общества дерматовенерологов и косметологов

Москва

Bakulev Andrey L., Dr Med Sci (habil.), professor, professor at Dept of Dermatovenereology and Cosmetology, member of the Specialized Commission of the Expert Council of the Ministry of Health of the Russian Federation on Dermatovenereology and Cosmetology, member of the Board of the Russian Society of Dermatovenereologists and Cosmetologists

Moscow

Хайрутдинов

В. Р.

Khairutdinov

V. R.

Хайрутдинов Владислав Ринатович, д.м.н., профессор кафедры дерматовенерологии, врач высшей квалификационной категории

Москва

Khairutdinov Vladislav R., Dr Med Sci (habil.), professor at Dept of Dermatovenereology, physician of the highest qualification category

Moscow

Переверзина

Н. О.

Pereverzina

N. O.

Переверзина Наталья Олеговна, к. м. н., врач-дерматовенеролог, зав. отделением дерматологии, лечебной и реабилитационной косметологии

Москва

Pereverzina Natalia O., PhD Med Sci, dermatovenerologist, head of Dept of Dermatology, Therapeutic and Rehabilitative Cosmetology

Moscow

Мурашкин

Н. Н.

Murashkin

N. N.

Мурашкин Николай Николаевич, д.м.н., профессор, руководитель НИИ детской дерматологии

Москва

Murashkin Nikolay N., Dr Med Sci (habil.), professor, head of Research Institute of Pediatric Dermatology

Moscow

Шатохина

Е. А.

Shatokhina

E. A.

Шатохина Евгения Афанасьевна, д.м.н., профессор кафедры дерматовенерологии и косметологии, ведущий научный сотрудник отдела внутренних болезней

Москва

Shatokhina Evgeniya A., Dr Med Sci (habil.), professor at Dept of Dermatovenereology and Cosmetology, leading researcher at Dept of Internal Diseases

Moscow

Хотко

А. А.

Khotko

A. A.

Хотко Алкес Асланчериевич, к.м.н., зам. главного врача по медицинской части

Краснодар

Khotko Alkes A., PhD Med Sci, deputy chief physician for Medical Affairs

Krasnodar

Руднева

Н. С.

Rudneva

N. S.

Руднева Наталья Сергеевна, к. м.н., главный врач, главный внештатный специалист дерматовенеролог, косметолог Министерства здравоохранения Тульской области, доцент кафедры пропедевтики внутренних болезней, курса дерматовенерологии

Тула

Rudneva Natalya S., PhD Med Sci, chief physician, chief dermatovenereologist, and cosmetologist at the Tula Region Ministry of Health; associate professor at Dept of Internal Medicine Propaedeutics and the Dermatovenereology Course

Tula

Владимирова

И. С.

Vladimirova

I. S.

Владимирова Ирина Сергеевна, к. м.н., врач-дерматовенеролог, старший преподаватель кафедры кожных и венерических болезней

Санкт-Петербург

Vladimirova Irina S., PhD Med Sci, dermatovenerologist, senior lecturer at Dept of Skin and Venereal Diseases

St. Petersburg

Сидоренко

О. А.

Sidorenko

O. A.

Сидоренко Ольга Анатольевна, д.м.н., профессор, зав. кафедрой кожных и венерических болезней

Ростов-на-Дону

Sidorenko Olga A., Dr Med Sci (habil.), professor, head of Dept of Skin and Venereal Diseases

Rostov‑on‑Don

Сергеева

И. Г.

Sergeeva

I. G.

Сергеева Ирина Геннадьевна, д. м.н., профессор кафедры фундаментальной медицины, врач-дерматовенеролог высшей категории, врач-онколог

Новосибирск

Sergeeva Irina G., Dr Med Sci (habil.), professor at Dept of Fundamental Medicine, dermatovenerologist of the highest category, oncologist

Novosibirsk

Винник

Ю. Ю.

Vinnik

Yu. Yu.

Винник Юрий Юрьевич, д.м.н., профессор кафедры дерматовенерологии с курсом косметологии и ПО (последипломного образования) им. проф. В.И. Прохоренкова, профессор кафедры урологии, андрологии и сексологии ИПО (Институт профессионального образования), андролог, венеролог, дерматолог, уролог

Красноярск

Vinnik Yuri Yu., Dr Med Sci (habil.), professor at Dept of Dermatovenereology with a Course in Cosmetology and Postgraduate Education named after prof. V. I. Prokhorenkov, professor at Dept of Urology, Andrology and Sexology of theInstitute of Professional Education, andrologist, venereologist, dermatologist, urologist

Krasnoyarsk

Городничев

П. В.

Gorodnichev

P. V.

Городничев Павел Викторович, врач-дерматовенеролог, специалист высшей квалификационной категории, зам. директора филиала по лечебной работе

Нижний Новгород

Gorodnichev Pavel V., dermatovenerologist, specialist of the highest qualification category, deputy director of the branch for Medical Work

Nizhny Novgorod

Хисматуллина

З. Р.

Khismatullina

Z. R.

Хисматуллина Зарема Римовна, д.м.н., профессор, зав. кафедрой дерматологии с курсом косметологии

Республика Башкортостан, г. Уфа

Khismatullina Zarema R., Dr Med Sci (habil.), professor, head of Dept of Dermatology with a Course of Csmetology

Republic of Bashkortostan, Ufa

ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской ФедерацииРоссияCentral State Medical Academy of the Administrative Department of the President of RussiaRussian Federation

ФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Минздрава РоссииРоссияV. A. Almazov National Medical Research CenterRussian Federation

ФГБУ «Национальный медицинский исследовательский центр оториноларингологии Федерального медико-биологического агентства»РоссияNational Medical Research Center of Otolaryngology of the Federal Medical and Biological AgencyRussian Federation

ФГАУ «Национальный медицинский исследовательский центр здоровья детей»РоссияNational Medical Research Center for Children’s HealthRussian Federation

ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской Федерации ; ФГБУ ВО «Московский государственный университет имени М.В. Ломоносова» ; ФГБОУ ВО «Университетская клиника Медицинского научно-образовательного института МГУ им. М. В. Ломоносова»РоссияCentral State Medical Academy of the Administrative Department of the President of Russia ; Lomonosov Moscow State University ; University Clinic of the Medical Research and Educational Institute of Lomonosov Moscow State UniversityRussian Federation

ГБУЗ «Клинический кожно-венерологический диспансер» Минздрава Краснодарского краяРоссияClinical Dermatovenereology Dispensary of the Ministry of Health of Krasnodar KraiRussian Federation

ГУЗ «Тульский областной клинический кожно-венерологический диспансер»РоссияTula Regional Clinical Dermatovenereological DispensaryRussian Federation

СПб ГБУЗ «Кожно-венерологический диспансер № 10 – Клиника дерматологии и венерологии» ; ФГБВОУ ВО «Военно-медицинская академия имени С. М. Кирова» Министерства обороны Российской ФедерацииРоссияSkin and Venereal Diseases Dispensary No. 10 – Clinic of Dermatology and Venereology ; S. M. Kirov Military Medical AcademyRussian Federation

ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава РоссииРоссияRostov State Medical UniversityRussian Federation

ФГАОУ ВО «Новосибирский национальный исследовательский государственный университет» ; ФГБНУ «Научно-исследовательский институт фундаментальной и клинической иммунологии» Клиника Иммунопатологии НИИФКИРоссияNovosibirsk National Research State University ; Research Institute of Fundamental and Clinical Immunology (Immunopathology Clinic)Russian Federation

ФГБОУ ВО «Красноярский государственный медицинский университет имени профессора В. Ф. Войно-Ясенецкого» Минздрава РоссииРоссияKrasnoyarsk State Medical University named after Professor V. F. Voyno‑YasenetskyRussian Federation

Нижегородский филиал ФГБУ «Государственный центр дерматовенерологии и косметологии» Минздрава РоссииРоссияNizhny Novgorod branch of the State Center for Dermatovenereology and CosmetologyRussian Federation

ФГБОУ ВО «Башкирский государственный медицинский университет»РоссияBashkir State Medical UniversityRussian Federation

2026

14042026

Дерматология (1)

8492

Copyright © Круглова Л.С., Бакулев А.Л., Хайрутдинов В.Р., Переверзина Н.О., Мурашкин Н.Н., Шатохина Е.А., Хотко А.А., Руднева Н.С., Владимирова И.С., Сидоренко О.А., Сергеева И.Г., Винник Ю.Ю., Городничев П.В., Хисматуллина З.Р., 2026

2026

Круглова Л.С., Бакулев А.Л., Хайрутдинов В.Р., Переверзина Н.О., Мурашкин Н.Н., Шатохина Е.А., Хотко А.А., Руднева Н.С., Владимирова И.С., Сидоренко О.А., Сергеева И.Г., Винник Ю.Ю., Городничев П.В., Хисматуллина З.Р.

Kruglova L.S., Bakulev A.L., Khairutdinov V.R., Pereverzina N.O., Murashkin N.N., Shatokhina E.A., Khotko A.A., Rudneva N.S., Vladimirova I.S., Sidorenko O.A., Sergeeva I.G., Vinnik Y.Y., Gorodnichev P.V., Khismatullina Z.R.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-alphabet.com/jour/article/view/4956

Псориаз оказывает выраженное негативное воздействие на качество жизни пациентов, включая социальную стигматизацию, а также связан с различными коморбидными патологиями, в том числе психосоциальными проблемами. Несмотря на множество научных исследований, различных подходов ведения пациентов, наличие современных препаратов, все еще остается ряд проблем и задач, которые стоят перед медицинским сообществом, включая вопросы стратификации категорий пациентов, представляющих сложности в их ведения. В статье представлены результаты консенсуса российских экспертов по формированию определений «Сложный для ведения» и «Трудный для лечения» пациент при псориазе и ведению этих больных.

Psoriasis has a significant negative impact on patients’ quality of life, including social stigma, and is associated with various comorbidities, including psychosocial problems. Despite numerous scientific studies, various patient management approaches, and the availability of modern medications, a number of problems and challenges remain for the medical community, including the stratification of patient categories that present challenges. This article presents the results of a Russian expert consensus on defining and managing the definitions of «Difficult to Manage» and «Hard to Treat» patients with psoriasis.

псориазгенно-инженерная терапия«сложный для ведения» пациент«трудный для лечения»делфийский консенсус

psoriasisgenetic engineering therapy«difficult to manage» patients«difficult to treat» Delphi consensus

References1

van Ee I, Deprez E, Egeberg A, et al. Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. J Eur Acad Dermatol Venereol. 2022; 36 (3): 403–412. DOI: 10.1111/jdv.17829

Zusman EZ, Howren AM, Park JYE, Dutz J, De Vera MA. Epidemiology of depression and anxiety in patients with psoriatic arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020; 50 (6). DOI: 10.1016/j.semarthrit.2020.02.001] [Zhao SS, Miller N, Harrison N, Duffield SJ, Dey M, Goodson NJ. Systematic review of mental health comorbidities in psoriatic arthritis. Clin Rheumatol. 2020; 39 (1): 217–225. DOI: 10.1007/s10067-019-04734-8

Zusman EZ, Howren AM, Park JYE, Dutz J, De Vera MA. Epidemiology of depression and anxiety in patients with psoriatic arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020; 50 (6). DOI: 10.1016/j.semarthrit.2020.02.001 [Zhao SS, Miller N, Harrison N, Duffield SJ, Dey M, Goodson NJ. Systematic review of mental health comorbidities in psoriatic arthritis. Clin Rheumatol. 2020; 39 (1): 217–225. DOI: 10.1007/s10067-019-04734-8

Coates LC, Orbai A-M, Azevedo VF, et al. Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the psoriatic arthritis impact of disease (PsAID) questionnaire. Health Qual Life Outcomes 2020; 18: 173. 10.1186/s12955-020-01422-z

Scala E, Mercurio L, Albanesi C, Madonna S. The Intersection of the Pathogenic Processes Underlying Psoriasis and the Comorbid Condition of Obesity. Life (Basel). 2024; 14 (6): 733. Published 2024 Jun 7. DOI: 10.3390/life14060733

Lubrano E, Scriffignano S, Azuaga AB. Impact of comorbidities on disease activity, patient global assessment and function in Psoriatic Arthritis: A Cross-Sectional Study. Rheumatol Ther. 2020; 7: 825–836. DOI: 10.1007/s40744-020-00229-0

Переверзина Н.О., Круглова Л.С., Коротаева Т.В., Руднева Н.С. Раннее назначение генно-инженерных биологических препаратов как эффективная вторичная профилактика псориатического артрита. Медицинский алфавит. 2025; (23): 33–38. https://doi.org/10.33667/2078-5631-2025-23-33-38

Pereverzina N.O., Kruglova L.S., Korotaeva T.V., Rudneva N.S. Early administration of genetically engineered biological drugs as effective secondary prevention of psoriatic arthritis. Medical alphabet. 2025; (23): 33–38. (In Russ.). https://doi.org/10.33667/2078-5631-2025-23-33-38

Ribeiro AL, Singla S, Chandran V, et al. Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals. Rheumatol Adv Pract. 2024; 8 (3): rkae074. Published 2024 Jun 19. DOI: 10.1093/rap/rkae074

Singla S, Ribeiro A, Torgutalp M, Mease PJ, Proft F. Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project. RMD Open. 2024; 10 (1): e003809. Published 2024 Jan 8. doi: 10.1136/rmdopen-2023–003809

Nagy G, Roodenrijs NMT, Welsing PMJ, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022; 81 (1): 20–33. DOI: 10.1136/annrheumdis-2021-220973

Sewerin P, Borchert K, Meise D, et al. Real-world treatment persistence with biologic disease-modifying antirheumatic drugs among German patients with psoriatic arthritis – a retrospective database study. Rheumatol Ther. 2021; 8: 483–497. DOI: 10.1007/s40744-021-00286-z

Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020; 79: 700–712. DOI: 10.1136/annrheumdis-2020–2171159

Glintborg B, Di Giuseppe D, Wallman JK, et al. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann Rheum Dis.2023; 82: 820–828. DOI: 10.1136/ard-2022–223650

Nicolescu A.C. et al. Psoriasis management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness // Life. 2022. Т. 12. № . 12. С. 2050.

Sarma N. Evidence and suggested therapeutic approach in psoriasis of difficult-to-treat areas: palmoplantar psoriasis, nail psoriasis, scalp psoriasis, and intertriginous psoriasis // Indian Journal of Dermatology. 2017. Т. 62. № . 2. С. 113–122.

Mastorino L. et al. Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult-to-treat population // British Journal of Dermatology. 2022. Т. 187. № . 2. С. 263–265

Magnano M. et al. Secukinumab in multi-failure psoriatic patients: the last hope? // Journal of Dermatological Treatment. 2018. Т. 29. № . 6. С. 583–585.

Megna M, Fabbrocini G, Ruggiero A, Cinelli E. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: preliminary data of a real-life 16- week retrospective study. Dermatol Ther 2020; 33: e14144.

Bonifati C, Morrone A, Cristaudo A, Graceffa D. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience. Dermatol Ther 2021; 34: e14584.

Lorenzin M, Ortolan A, Cozzi G et al. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study. Clin Rheumatol 2021; 40: 4569–80.

Nast A, Smith C, Spuls PI et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris – part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021; 35: 281–317.

Radtke M.A., Reich K., Spehr C., Augustin M. Treatment goals in psoriasis routine care. Arch Dermatol Res. 2015 Jul; 307 (5): 445–9.

Круглова, Л.С. Новый подход к ведению пациентов с псориазом кожи и аксиальными поражениями: ранняя диагностика и ускоренная терапия / Л.С. Круглова, Н.О. Переверзина, Н.С. Руднева // Эффективная фармакотерапия. 2023. Т. 19, № 19. С. 6–14. DOI 10.33978/2307-3586-2023-19-19-6-14

Kruglova, L. S. A new approach to the management of patients with skin psoriasis and axial lesions: early diagnosis and accelerated therapy / L.S. Kruglova, N.O. Pereverzina, N.S. Rudneva // Effective pharmacotherapy. 2023. Vol. 19, No. 19. Pp. 6–14. (In Russ.). DOI 10.33978/2307-3586-2023-19-19-6-14

Strober B.E., Clay Cather J., Cohen D., Crowley J.J., Gordon K.B., Gottlieb A.B., Kavanaugh A.F., Korman N.J., Krueger G.G., Leonardi C.L. et al. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb). 2012 Dec; 2 (1):1. Epub 2012 Mar 17.

Strober B.E., Clay Cather J., Cohen D., Crowley J.J., Gordon K.B., Gottlieb A.B., Kavanaugh A.F., Korman N.J., Krueger G.G., Leonardi C.L. et al A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part. 2. Dermatol Ther (Heidelb). 2012 Dec; 2 (1): 2. Epub 2012 Mar 30]

Schett G, Rahman P, Ritchlin C, et al. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022; 18 (6):311–325. DOI: 10.1038/s41584–022–00776–6

Becher Strand et al/ Immunogenicity of biologics in chronic inflammatory diseases. A systematic review. BioDrugs 2017; 31 (4): 299–316.

Bakulev A.L. The actual challenges of biologics treatment in patients with psoriasis // Vestnik dermatologii i venerologii. 2020. Т. 96. № . 2. С. 51–57.

Augustin M., Thaci D., Eyerich K., Pinter A., Radtke M., Lauffer F., Mrowietz U., Gerdes S., Pariser D., Lebwohl M., Sieder C., Melzer N., Reich K. Continued treatment with secukinumab is associated with high retention

Shahwan KT, Kimball AB. Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. Int J Womens Dermatol. 2016 Oct 26; 2 (4): 151–153. DOI: 10.1016/j.ijwd.2016.09.003. PMID: 28492030; PMCID: PMC5419024.

Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012; 71 (8): 1267–1272. DOI: 10.1136/annrheumdis-2011–201273.

Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019; 20 (7): 863–872. DOI: 10.1080/14656566.2019.1583207

Currado D, Trunfio F, Saracino F, et al. Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients. RMD Open. 2025; 11 (2): e005717. DOI: 10.1136/rmdopen-2025–005717

Patsalos O, Dalton B, Leppanen J, Ibrahim MAA, Himmerich H. Impact of TNF-α Inhibitors on Body Weight and BMI: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020; 11: 481. Published 2020 Apr 15. DOI: 10.3389/fphar.2020.00481

Gialouri CG, Evangelatos G, Fragoulis GE. Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?. Mediterr J Rheumatol. 2022; 33 (Suppl 1): 150–161. Published 2022 Apr 15. DOI: 10.31138/mjr.33.1.150

Siebert S, Sattar N, Ferguson LD. Weighing in on obesity and psoriatic arthritis – Time to move beyond association to robust randomised trials. Joint Bone Spine. 2025; 92 (5): 105904. DOI: 10.1016/j.jbspin.2025.105904

Carter K, Cheung WY, Hutchings HA, et al. The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT. Southampton (UK): National Institute for Health and Care Research; February 2025

da Silva BS, Bonfá E, de Moraes JC, et al. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologicals. 2010; 38 (5): 567–569. DOI: 10.1016/j.biologicals.2010.05.003

Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011; 305 (24): 2525–2531. DOI: 10.1001/jama.2011.878

Puig L, Korman N, Greggio C, Cirulli J, Teng L, Chandran V, et al. Long-term hemoglobin A1c changes with apremilast in patients with psoriasis and psoriatic arthritis: pooled analysis of phase 3 ESTEEM and PALACE trials and phase 3b LIBERATE trial. J Am Acad Dermatol. 2019; 81: 89. DOI: 10.1016/j.jaad.2019.06.346

Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30(2):96–102. DOI: 10.1002/dmrr.2486

Katsuyama T, Sada KE, Namba S, et al. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res Clin Pract. 2015; 108 (2): 273–279. DOI: 10.1016/j.diabres.2015.02.010

Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014; 73 (6): 1157–1162. DOI: 10.1136/annrheumdis-2012–202812

Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther. 2019; 21 (1): 17. DOI: 10.1186/s13075-019-1810-5

Nicolau J, Nadal A, Sanchís P, Pujol A, Nadal C, Masmiquel L. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023; 161 (7): 293–296. DOI: 10.1016/j.medcli.2023.05.021

Коротаева Т.В., Трошина Е.А., Лила А.М., Паневин Т.С., Насонов Е.Л., Корсакова Ю.Л., Глухова С.И. Эффективность лираглутида в комплексной терапии больных псориазом в сочетании с метаболическими нарушениями: метаанализ наблюдательных и контролируемых исследований. Ожирение и метаболизм. 2025; 22 (2): 70–76.

Korotaeva T.V., Troshina E.A., Lila A.M., Panevin T.S., Nasonov E.L., Korsakova Yu.L., Glukhova S.I. Efficacy of liraglutide in combination therapy of patients with psoriasis combined with metabolic disorders: a meta-analysis of observational and controlled studies. Obesity and Metabolism. 2025; 22 (2): 70–76. (In Russ.).

Maglio C, Peltonen M, Rudin A, Carlsson LMS. Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish obese subjects study. Obesity (Silver Spring). 2017; 25 (12): 2068–2073. DOI: 10.1002/oby.21955

Egeberg A, Sørensen JA, Gislason GH, et al. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery [published correction appears in JAMA Surg. 2018; 153 (7): 692]. JAMA Surg. 2017;152(4):344–349. DOI: 10.1001/jamasurg.2016.4610

Goel N, Wallace EB, Lindsay C. Hot Topics: Depression in Individuals With Psoriasis and Psoriatic Arthritis. J Rheumatol. October 2024: jrheum. 2024–0362. DOI: 10.3899/jrheum.2024–0362

Bell KA, Balogh EA, Feldman SR. An update on the impact of depression on the treatment of psoriasis. Expert Opin Pharmacother. 2021; 22 (6). DOI: 10.1080/14656566.2020.1849141

Wang X, Wu L, Liu J, Ma C, Liu J, Zhang Q. The neuroimmune mechanism of pain induced depression in psoriatic arthritis and future directions. Biomedicine and Pharmacotherapy. 2025; 182. DOI: 10.1016/j.biopha.2024.117802

Mathew AJ, Chandran V. Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation. Rheumatol Ther. 2020; 7 (2). DOI: 10.1007/s40744-020-00207-6

Goel N, Wallace EB, Lindsay C. Hot Topics: Depression in Individuals With Psoriasis and Psoriatic Arthritis. J Rheumatol. October 2024: jrheum. 2024–0362. DOI: 10.3899/jrheum.2024–0362

Wang M, Sun Y, Sun Y. Efficacy and safety of drugs for psoriasis patients with mental disorders: A systematic review. J Affect Disord. 2024; 365: 112–125. DOI: 10.1016/j.jad.2024.08.077

Sood A, Raji MA. Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs. Clin Rheumatol. 2021; 40 (4). DOI: 10.1007/s10067-020-05372-1

Reich K, Foley P, Han C, et al. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE2 comparator study versus adalimumab. J Dermatolog Treat. 2020; 31 (6): 617–623. DOI: 10.1080/09546634.2019.1628172

Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022; 386 (4): 316–326. DOI: 10.1056/NEJMoa2109927

Curtis JR, Yamaoka K, Chen YH, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023; 82 (3): 331–343. DOI: 10.1136/ard-2022–222543

Raaschou P, Simard JF, Holmqvist M, Askling J; ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013; 346: f1939. DOI: 10.1136/bmj.f1939

Raaschou P, Frisell T, Askling J; ARTIS Study Group. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2015; 74 (12): 2137–2143. DOI: 10.1136/annrheumdis-2014–205745

Phillips C, Zeringue AL, McDonald JR, Eisen SA, Ranganathan P. Tumor Necrosis Factor Inhibition and Head and Neck Cancer Recurrence and Death in Rheumatoid Arthritis. PLoS One. 2015; 10 (11): e0143286. Published 2015 Nov 23. DOI: 10.1371/journal.pone.0143286

Sebbag E, Lauper K, Molina-Collada J, et al. 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. Ann Rheum Dis. Published online December 20, 2024. DOI: 10.1136/ard-2024–225982

Avouac J, Ait-Oufella H, Habauzit C, Benkhalifa S, Combe B. The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations. Rheumatol Ther. 2025; 12 (2): 211–236. DOI: 10.1007/s40744–025–00753-x

Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs. 2023; 37 (1): 35–55. DOI: 10.1007/s40259–022–00569-z

Poizeau F, Nowak E, Kerbrat S, et al. Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab. JAMA Dermatol. 2020; 156 (11): 1208–1215. DOI: 10.1001/jamadermatol.2020.2977

Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013; 27 (12): 1535–1545. DOI: 10.1111/jdv.12046

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T. Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies. Cutis. 2018; 101 (1): 38;42;56.

Pangilinan MCG, Sermswan P, Asawanonda P. Use of anti-IL-17 monoclonal antibodies in HIV patients with Erythrodermic Psoriasis. Case Rep Dermatol. 2020; 12 (2): 132–7.

Di Lernia V, Casanova DM, Garlassi E. Secukinumab in an HIV-positive patient with psoriasis. J Dtsch Dermatol Ges. 2019; 17 (6): 646–8.

Bartos G, Cline A, Beroukhim K, Burrall BA, Feldman SR. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. Dermatol Online J. 2018; 24 (11): 13030.

Myers B, Thibodeaux Q, Reddy V, et al. Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review. J Psoriasis Psoriatic Arthritis. 2021; 6 (1): 19–26. DOI: 10.1177/2475530320954279

Saeki H, Ito T, Hayashi M, et al. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection. J Eur Acad Dermatol Venereol. 2015;29(8):1653–1655. doi:10.1111/jdv.12531.

Qian F, Yan Y, Huang J, et al. Use of ixekizumab in an HIV-positive patient with psoriatic arthritis. Int J STD AIDS. 2022; 33 (5): 519–521. DOI: 10.1177/09564624221076289

Orsini D, Maramao FS, Gargiulo L, et al. Effectiveness and safety of risankizumab in HIV patients with psoriasis: A case series. Int J STD AIDS. 2024; 35 (1): 67–70. DOI: 10.1177/09564624231199510

Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016; 22 (28): 6444–55.

Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Prac‑ tical Considerations. Am J Clin Dermatol. 2019; 20 (6): 829–845. DOI: 10.1007/s40257‑019‑00457‑3

Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate‑to‑se‑ vere plaque psoriasis. J Eur Acad Dermatol Venereol. 2017; 31 (5): 774–790. DOI: 10.1111/jdv.14114

Cannizzaro MV, Franceschini C, Esposito M, Bianchi L, Giunta A. Hepatitis B reactivation in psoriasis patients treated with anti‑TNF agents: prevention and management. Psoriasis (Auckl). 2017; 7: 35–40. Published 2017 Apr 15. DOI: 10.2147/PTT.S108209

Koskinas J, Tampaki M, Doumba PP, Rallis E. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface‑antigen‑negative anti‑HBs‑positive patient. Br J Dermatol. 2013; 168 (3): 679–680. DOI: 10.1111/bjd.12120

Crowley J, Thaçi D, Joly P, et al. Long‑term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017; 77 (2): 310–317.e1. DOI: 10.1016/j.jaad.2017.01.052

Crowley JJ, Warren RB, Cather JC. Safety of selective IL‑23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019; 33 (9): 1676–1684. DOI: 10.1111/jdv.15653]

Crowley JJ, Warren RB, Cather JC. Safety of selective IL‑23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019; 33 (9): 1676–1684. DOI: 10.1111/jdv.15653

Torres T, Chiricozzi A, Puig L, et al. Treatment of Psoriasis Patients with Latent Tuberculosis Using IL‑17 and IL‑23 Inhibitors: A Retrospective, Multinational, Multicentre Study. Am J Clin Dermatol. 2024; 25 (2): 333–342. DOI: 10.1007/s40257–024–00845–4

Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta‑analysis of randomised controlled trials. BMJ Open. 2017; 7 (3): e012567. DOI: 10.1136/bmjopen‑2016–012567

Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015; 14 (6): 503–509. DOI: 10.1016/j.autrev.2015.01.011

The authors declare that there are no conflicts of interest present.